{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:42:09Z","timestamp":1792456929499,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40265-017-0779-0","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T13:50:45Z","timestamp":1497361845000},"page":"1251-1259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Midostaurin: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"779_CR1","unstructured":"Novartis Pharmaceuticals Corp. RYDAPT\u00ae (midostaurin) capsules: US prescribing information. 2017. https:\/\/www.fda.gov . Accessed 17 May 2017."},{"key":"779_CR2","first-page":"215","volume-title":"Targeted therapy of acute myeloid leukemia","author":"N Daver","year":"2014","unstructured":"Daver N, Ravandi F. FLT3 in AML. In: Andreeff M, editor. Targeted therapy of acute myeloid leukemia. New York: Springer; 2014. p. 215\u201331."},{"key":"779_CR3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-0-387-73744-7_18","volume-title":"Rare hematological malignancies","author":"P Valent","year":"2008","unstructured":"Valent P. Systemic mastocytosis. In: Ansell SM, editor. Rare hematological malignancies. New York: Springer Science\u00a0+\u00a0Business Media; 2008. p. 399\u2013419."},{"issue":"1","key":"779_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53\u201361.","journal-title":"Blood"},{"issue":"29","key":"779_CR5","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264\u201374.","journal-title":"J Clin Oncol"},{"key":"779_CR6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4939-1393-0_10","volume-title":"Targeted therapy of acute myeloid leukemia","author":"G Motyckova","year":"2015","unstructured":"Motyckova G, Stone RM. Development of midostaurin as a tyrosine kinase inhibitor. In: Andreeff M, editor. Targeted therapy of acute myeloid leukemia. New York: Springer; 2015. p. 201\u201314."},{"key":"779_CR7","unstructured":"US FDA. Midostaurin [media release]. 28 Apr 2017. https:\/\/www.fda.gov ."},{"key":"779_CR8","unstructured":"US FDA. FDA approves new combination treatment for acute myeloid leukemia [media release]. 28 Apr 2017. https:\/\/www.fda.gov ."},{"key":"779_CR9","unstructured":"US FDA. Premarket approval (PMA): LeukoStrat CDx FLT3 mutation assay. 2017. https:\/\/www.fda.gov . Accessed 18 May 2017."},{"key":"779_CR10","unstructured":"Adis Insight. Drug profile: midostaurin. 2017. http:\/\/adisinsight.springer.com\/ . Accessed 17 May 2017."},{"issue":"5","key":"779_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433\u201343.","journal-title":"Cancer Cell"},{"issue":"2","key":"779_CR12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","volume":"30","author":"B Peter","year":"2016","unstructured":"Peter B, Winter GE, Blatt K, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30(2):464\u201372.","journal-title":"Leukemia"},{"issue":"5","key":"779_CR13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00280-012-1825-y","volume":"69","author":"A Corral del","year":"2012","unstructured":"del Corral A, Dutreix C, Huntsman-Labed A, et al. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemother Pharmacol. 2012;69(5):1255\u201363.","journal-title":"Cancer Chemother Pharmacol"},{"key":"779_CR14","doi-asserted-by":"crossref","unstructured":"Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18\u201360 with FLT3 mutations (muts): an international prospective randomized (rand) p-controlled double-blind trial (CALGB 10603\/RATIFY [Alliance]) [abstract no. 6]. Blood. 2015;126(23).","DOI":"10.1182\/blood.V126.23.6.6"},{"issue":"9","key":"779_CR15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","volume":"26","author":"RM Stone","year":"2012","unstructured":"Stone RM, Fischer T, Paquette R, et al. Phase Ib study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"779_CR16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54\u201360.","journal-title":"Blood"},{"issue":"28","key":"779_CR17","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, Deangelo DJ, et al. Phase IIb trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339\u201345.","journal-title":"J Clin Oncol"},{"key":"779_CR18","doi-asserted-by":"crossref","unstructured":"Schlenk R, Dohner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606) [abstract no. 322]. Blood. 2015;126(23).","DOI":"10.1182\/blood.V126.23.322.322"},{"key":"779_CR19","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Patnaik MM, Scott BL, et al. Radius: a phase 2, randomized trial of standard of care (SOC) with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients (pts) with FLT3-Itd-mutated acute myeloid leukemia (AML) [abstract no. 2248]. Blood. 2016;128(22).","DOI":"10.1182\/blood.V128.22.2248.2248"},{"key":"779_CR20","unstructured":"National Library of Medicine. Clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov . Accessed 22 May 2017."},{"key":"779_CR21","doi-asserted-by":"crossref","unstructured":"Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015;15(7):428\u201332.e2.","DOI":"10.1016\/j.clml.2015.02.017"},{"issue":"4","key":"779_CR22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.23924","volume":"90","author":"P Strati","year":"2015","unstructured":"Strati P, Kantarjian H, Ravandi F, et al. Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276\u201381.","journal-title":"Am J Hematol"},{"issue":"12","key":"779_CR23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1316","volume":"33","author":"CB Williams","year":"2013","unstructured":"Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed\/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013;33(12):1341\u201352.","journal-title":"Pharmacotherapy."},{"issue":"26","key":"779_CR24","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530\u201341.","journal-title":"N Engl J Med"},{"key":"779_CR25","doi-asserted-by":"crossref","unstructured":"Gotlib J, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial [abstract no. 316]. Blood. 2010;116(21).","DOI":"10.1182\/blood.V116.21.316.316"},{"issue":"Suppl 1","key":"779_CR26","first-page":"96","volume":"101","author":"B Anrooij Van","year":"2016","unstructured":"Van Anrooij B, Oude Elberink J, Span L, et al. Midostaurin (PKC412) in indolent systemic mastocytosis: a phase 2 trial [abstract no. P303]. Haematologica. 2016;101(Suppl 1):96\u20137.","journal-title":"Haematologica"},{"key":"779_CR27","unstructured":"Novartis. Novartis drug PKC412 (midostaurin) granted FDA priority review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis [media release]. 14 Nov 2016. https:\/\/www.novartis.com ."},{"key":"779_CR28","unstructured":"Invivoscribe Technologies Inc. Invivoscribe\u2122 announces collaboration agreement to develop companion diagnostic test [media release]. 15 Feb 2011. http:\/\/www.marketwired.com ."},{"key":"779_CR29","unstructured":"Invivoscribe. Invivoscribe\u00ae received FDA approval for the LeukoStrat\u00ae CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt\u00ae and is the first companion diagnostic for AML [media release]. 28 Apr 2017. https:\/\/invivoscribe.com ."},{"key":"779_CR30","unstructured":"Takara Bio. Takara Bio licenses FLT3 gene mutation detection method to InVivoScribe Technologies [media release]. 12 July 2006. http:\/\/www.japancorp.net ."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0779-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T03:35:22Z","timestamp":1602300922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0779-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0779-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}